ATE314847T1 - Neue verwendung von hiv-protease hemmern - Google Patents

Neue verwendung von hiv-protease hemmern

Info

Publication number
ATE314847T1
ATE314847T1 AT99923725T AT99923725T ATE314847T1 AT E314847 T1 ATE314847 T1 AT E314847T1 AT 99923725 T AT99923725 T AT 99923725T AT 99923725 T AT99923725 T AT 99923725T AT E314847 T1 ATE314847 T1 AT E314847T1
Authority
AT
Austria
Prior art keywords
proteasome
activity
saquinavir
hiv protease
hiv
Prior art date
Application number
AT99923725T
Other languages
English (en)
Inventor
Patrice Andre
Vincent Lotteau
Rolf Zinkernagel
Paul Klenerman
Marcus Groettrup
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE314847T1 publication Critical patent/ATE314847T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99923725T 1998-06-11 1999-06-11 Neue verwendung von hiv-protease hemmern ATE314847T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9807373A FR2779653B1 (fr) 1998-06-11 1998-06-11 Utilisation de composes modulateurs du proteasome en therapie

Publications (1)

Publication Number Publication Date
ATE314847T1 true ATE314847T1 (de) 2006-02-15

Family

ID=9527279

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923725T ATE314847T1 (de) 1998-06-11 1999-06-11 Neue verwendung von hiv-protease hemmern

Country Status (10)

Country Link
US (2) US6506555B1 (de)
EP (2) EP1083898B1 (de)
JP (1) JP2002517441A (de)
AT (1) ATE314847T1 (de)
AU (1) AU4049399A (de)
CA (1) CA2334990A1 (de)
DE (1) DE69929330T2 (de)
ES (1) ES2258842T3 (de)
FR (1) FR2779653B1 (de)
WO (1) WO1999063998A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
PT1326632E (pt) * 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
DE10051716A1 (de) * 2000-10-12 2002-04-25 Ulrich Schubert Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren
ITRM20010210A1 (it) * 2001-04-18 2002-10-18 Ist Superiore Sanita Uso degli inibitori della proteasi del virus dell'immunodeficienza umana (hiv)nella terapia del sarcoma di kaposi, dei tumori e delle malatt
EP1453504A1 (de) * 2001-12-14 2004-09-08 Cedars-Sinai Medical Center Verwendung von hiv-1 protease hemmern und ihrer derivate bei entzündung
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
US20050020580A1 (en) * 2002-12-23 2005-01-27 Badley Andrew D. Materials and methods for the prevention or treatment of apoptosis and apoptosis-related diseases and conditions
PT1677827E (pt) * 2003-10-27 2009-03-13 Vertex Pharma Associações para o tratamento do vhc
EP1804821A4 (de) * 2004-10-01 2009-07-15 Vertex Pharma Hcv ns3-ns4a protease-hemmung
AP2985A (en) * 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
US20100292129A1 (en) 2007-05-24 2010-11-18 Daniel Finley Methods and Compositions for Enhancing Proteasome Activity
EP2214668A1 (de) * 2007-10-29 2010-08-11 Cipla Limited Neue antiretrovirale kombination
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
US20150283127A1 (en) * 2012-11-20 2015-10-08 Onconox Aps Saquinavir-no for immunomodulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
DE69332616T2 (de) * 1992-12-29 2003-11-06 Abbott Lab Hemmer der retroviralen Protease
CA2155554A1 (en) * 1993-02-10 1994-08-18 Alfred L. Goldberg Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9503850D0 (en) 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
WO1998052571A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie

Also Published As

Publication number Publication date
CA2334990A1 (fr) 1999-12-16
DE69929330D1 (de) 2006-03-30
EP1083898A1 (de) 2001-03-21
EP1637139A2 (de) 2006-03-22
US20030082207A1 (en) 2003-05-01
FR2779653A1 (fr) 1999-12-17
WO1999063998A1 (fr) 1999-12-16
JP2002517441A (ja) 2002-06-18
EP1637139A3 (de) 2006-08-16
AU4049399A (en) 1999-12-30
EP1083898B1 (de) 2006-01-04
ES2258842T3 (es) 2006-09-01
FR2779653B1 (fr) 2002-12-20
US6506555B1 (en) 2003-01-14
DE69929330T2 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
ATE314847T1 (de) Neue verwendung von hiv-protease hemmern
ID21696A (id) Turunan asam antranilat sebagai modulator resistensi multi obat
AR003415A1 (es) Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.
TR200001998T1 (tr) Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
MY138860A (en) Hiv protease inhibitors.
DE68901805D1 (de) Durch waerme versiegelbare membrane fuer die transdermale abgabe von arzneimittelwirkstoffen.
HUP0101598A2 (hu) Aszpartil proteáz inhibitorok prodrugjai és ezeket tartalmazó gyógyszerkészítmények
ATE192921T1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ATE225647T1 (de) Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
ATE179164T1 (de) Hiv-proteaseinhibitoren
DE59305805D1 (de) Tilidin-dihydrogenorthophosphat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
AR008371A1 (es) Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
ES2127278T3 (es) Preparados de acidos 2-aril-propionicos y procedimiento para su produccion.
DE69830305D1 (de) Ortsspezifische arzneimittel verabreichung
NO963143D0 (no) Oral legemiddelform inneholdende colestipol som bærer med sure virkestoffer og fremgangsmåte ved fremstilling av denne
ES2043736T3 (es) Acidos 3,5-dihidroxi-heptanoicos sustituidos con (1h-pirrol-3-ilo) en posicion 7, sus correspondientes delta-lactonas y sales, procedimientos para su preparacion, su utilizacion como medicamentos, preparados farmaceuticos y productos intermedios.
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
GEP20022764B (en) HIV Protease Inhibitors, Pharmaceutical Compositions and Methods for Inhibiting HIV Protease
ATE110570T1 (de) Nephroprotektive infusionslösung.
ES2053834T3 (es) Un metodo para la preparacion de una sustancia terapeutica.
PT82842A (fr) Procede de preparation de l-di ou tripeptides possedant une activite biologique utilisable en medecine humaine et veterinaire et de medicaments les contenant
AR001687A1 (es) Producto farmacéutico apropiado para el tratamiento parenteral de daños producidos por enfermedades isquemicas focales permanentes que comprende (s)-adenosil-l-metionina (SAMe)
TH33140A (th) วิธีการเตรียมสารยับยั้ง hiv-โปรทีเอส และสารมัธยันตร์ สำหรับการเตรียมสารยับยั้ง hiv-โปรทีเอส

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties